Free Trial

HLS Therapeutics Q3 2023 Earnings Report

HLS Therapeutics logo
C$4.40 -0.20 (-4.35%)
As of 04/3/2025 03:59 PM Eastern

HLS Therapeutics EPS Results

Actual EPS
-C$0.28
Consensus EPS
-C$0.16
Beat/Miss
Missed by -C$0.12
One Year Ago EPS
N/A

HLS Therapeutics Revenue Results

Actual Revenue
$21.52 million
Expected Revenue
$21.97 million
Beat/Miss
Missed by -$450.00 thousand
YoY Revenue Growth
N/A

HLS Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Remove Ads

HLS Therapeutics Earnings Headlines

Q1 Earnings Estimate for TSE:HLS Issued By Stifel Canada
EU’s Action Takes Aim At US Retirees
Trump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and global powers like China, Russia, and even Europe rapidly moving away from the U.S. dollar, central banks and financial giants are frantically buying gold at historic rates. This massive shift threatens your retirement savings with inflation and market instability—potentially worse than 2008. But you can protect yourself today by leveraging a little-known IRS loophole that lets you diversify your IRA or 401(k) into gold—tax-free and penalty-free.
HLS Therapeutics Inc (HLS) Receives a Hold from Stifel Nicolaus
See More HLS Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HLS Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HLS Therapeutics and other key companies, straight to your email.

About HLS Therapeutics

HLS Therapeutics (TSE:HLS) Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.

View HLS Therapeutics Profile

More Earnings Resources from MarketBeat